Treatment of Chondroblastoma with Denosumab

• DOI: 10.2106/jbjs.cc.20.00178
• Publication Date: 2021-05-17T18:08:40Z
• Authors: Julia D. Visgauss; Alex Lazarides; Brendan Dickson; Diana Cardona; Maya Sheth; Suzanne Bartholf ...; Jason A. Somarelli; William C. Eward
• Keywords: Male; 0301 basic medicine; 03 medical and health sciences; Adolescent; Bone Density Conservation Agents; Receptor Activator of Nuclear Factor-kappa B; Chondroblastoma; Humans; Denosumab; Signal Transduction

Case: A 15-year-old boy with chondroblastoma of the right hemipelvis presented with significant periacetabular bone destruction. Neoadjuvant denosumab treatment facilitated initial joint preserving surgery. Unfortunately, he experienced 2 local recurrences and underwent wide surgical resection 2 years after his initial diagnosis.

Conclusion: Inhibition of the receptor activator of NF-κB (RANK)/RANK ligand (RANK-L) pathway with denosumab has been used neoadjuvantly for the treatment of giant cell tumor of bone, but its role in the treatment of chondroblastoma is less understood. This patient's clinical response and effect on cellular RANK/RANK-L activity support the consideration of denosumab in the treatment algorithm for other osteolytic bone tumors such as chondroblastoma.